The rapid mutation of the SARS-CoV-2 virus is now a major concern with no effective drugs and treatments. The severity of the disease is linked to the induction of a cytokine storm that promotes extensive inflammation in the lung, leading to many acute lung injuries, pulmonary edema, and eventually death. Mesenchymal stem cells (MSCs) might prove to be a treatment option as they have immunomodulation and regenerative properties. Clinical trials utilizing MSCs in treating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) have provided a basis in treating post-COVID-19 patients. In this review, we discussed the effects of MSCs as an immunomodulator to reduce the severity and death in patients with COVID-19, including the usage of MSCs as an alternative regenerative therapy in post-COVID-19 patients. This review also includes the current clinical trials in utilizing MSCs and their potential future utilization for long-COVID treatments.
【저자키워드】 immunomodulation, MSCs, long-COVID, regeneration, 【초록키워드】 Treatment, Inflammation, ARDS, Cytokine storm, clinical trial, therapy, Mutation, Trial, acute respiratory distress syndrome, severity, immunomodulation, lung, clinical trials, SARS-CoV-2 virus, Mesenchymal stem cells, MSCs, Lung injury, acute lung injury, immunomodulator, effective drugs, clinical, edema, death, Pulmonary edema, mesenchymal stem cell, regenerative, acute respiratory distress, MSC, Post-COVID-19 patients, respiratory distress, lung injuries, Usage, syndrome, Effect, eventually death, regenerative properties, include, the disease, provided, promote, reduce, effective drug, patients with COVID-19, the SARS-CoV-2 virus, 【제목키워드】 Capacity, MSC,